Commitments and Contingencies The Company's long-term contractual obligations include commitments and estimated purchase obligations entered into in the normal course of business. These obligations include commitments related to purchases of inventory of our products, research and development service agreements, income tax contingencies, operating leases, selling, general and administrative obligations, leased office space for our principal office in Parsippany, New Jersey and additional leased office space in San Diego, California, royalties, milestone payments and other contingent payments due under the Company's license and acquisition agreements. Future estimated contractual obligations as of December 31, 2015 are: Contractual Obligations (1) Less Than 1 Year 1-3 Years 3-5 Years More Than 5 Years Total (In thousands) Inventory related commitments $ 48,866 $  $  $  $ 48,866 Research and development 43,934 5,253 715  49,902 Operating leases 7,645 15,548 14,648 41,178 79,019 Selling, general and administrative 4,067 2,348 454  6,869 Total contractual obligations $ 104,512 $ 23,149 $ 15,817 $ 41,178 $ 184,656 _______________________________________ (1) This table does not include any milestone and royalty payments which may become payable to third parties for which the timing and likelihood of such payments are not known, as discussed below. It also does not include the long-term debt obligations. See Note 10 "Convertible Senior Notes" for further details. All of the inventory related commitments included above are non-cancellable. Included within the inventory related commitments above are purchase commitments for 2016 totaling $17.2 million and $25.1 million for Angiomax and Orbactiv bulk drug substances, respectively. Of the total estimated contractual obligations for research and development and selling, general and administrative activities, $19.5 million are non-cancellable. The Company leases its principal offices in Parsippany, New Jersey. The lease covers 173,146 square feet and expires January 2024